Analysis of cerebral protection compared to unprotected transcatheter aortic valve replacement


Cerebral protection and TAVI is a much discussed issue. Here A. Lansky invites us to consider the 148 patients that were treated using neuroprotection as compared to controls in this pooled patient level analysis highlighting the Triguard device.

Did they see a reduction in the levels of CNS infarction, total lesion volume or stroke? What are the next steps?